Correction to “Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study”
{"title":"Correction to “Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study”","authors":"","doi":"10.1111/dom.16381","DOIUrl":null,"url":null,"abstract":"<p>A modified Supplementary material file has been re-submitted online, which documents these changes.</p><p>These corrections in the <i>y</i>-axis scale do not affect any cumulative risk estimates in the original article. The trends in incidence rates also remain unchanged.</p><p>We apologize for this oversight and for any inconvenience caused.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 6","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16381","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16381","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
A modified Supplementary material file has been re-submitted online, which documents these changes.
These corrections in the y-axis scale do not affect any cumulative risk estimates in the original article. The trends in incidence rates also remain unchanged.
We apologize for this oversight and for any inconvenience caused.
期刊介绍：
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
